AFTX-201, Affinia's gene therapy program in BAG3 dilated cardiomyopathy, demonstrates efficacy, safety, and differentiation in a genetically relevant preclinical model, with full restoration of cardiac function Additional data show Affinia's gene therapy program in MYBPC3 hypertrophic...
Affinia Therapeutics to Highlight New Data on Genetic Cardiomyopathy Programs and BBB-Penetrant Capsids Leveraging Novel Receptors at the European Society of Gene & Cell Therapy 2024 31st Annual Congress
Seaking AlphaSeeking Alpha / Seaking Alpha 2 hours ago 1 Views
Comments